WLBU2

WLBU2 is an engineered cationic antimicrobial peptide (eCAP) designed to overcome the sensitivity issues of natural antimicrobial peptides (AMPs) in various environments. WLBU2 exhibits rapid bactericidal activity and has a minimum inhibitory concentration (MIC) value of ≤ 10 μM against numerous Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, and Escherichia coli. It effectively prevents biofilm formation by Pseudomonas aeruginosa and retains its activity in mucus-rich, low pH, and high salt conditions, without adverse effects on human respiratory epithelial cells. Additionally, WLBU2 is applicable for studying cystic fibrosis (CF) and Pseudomonas aeruginosa infections.